Navigation Links
Immune-Boost Treatment Might Help Some With Advanced Colon Cancer
Date:4/6/2011

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, April 6 (HealthDay News) -- By giving more intensive chemotherapy along with drugs designed to boost the body's own immune system, researchers were able to roughly double survival time for patients with advanced, metastatic colorectal cancer compared to patients receiving standard chemotherapy alone.

In fact, the trial, results of which are being presented at the annual meeting of the American Association for Cancer Research in Orlando, was stopped early because of the promising findings.

"With this study, we have produced for the first time strong proof-of-concept that chemo-immunotherapy may be active and more efficacious than standard [chemotherapy] in metastatic colon cancer patients," said study lead author Dr. Pierpaolo Correale, an oncologist with Siena University School of Medicine in Siena, Italy.

The standard of care right now for patients with colorectal cancer that's spread to other regions is to use one of two dual-drug combinations of chemotherapy alone, or use them alongside a newly developed monoclonal antibody treatment such as Avastin (bevacizumab) or Erbitux (cetuximab). These approaches can boost overall survival to about 20 to 22 months.

For this study, the research team randomized 130 patients to receive either chemotherapy alone (with a regimen known as FOLFOX) or to receive FOLFOX plus drugs to ramp up the immune system (this regimen is known as GOLFIG).

The chemo/immune boost approach involves first giving patients gemcitabine plus standard FOLFOX chemotherapy (oxaliplatin, levofolinic acid and 5-FU/GOLF) that targets and kills the cancer cells in a number of ways -- all the while sending off signals alerting the immune system to the cancer.

This is then followed up with the administration of signaling molecules called cytokines that spur key immune cells into action. Another immune-boosting cancer drug, called aldesleukine, is also given to help boost the population of immune cells targeted against tumor cells.

At the time of data collection, the patients treated with this approach have survived an average 16.5 months without a relapse, compared with just 7.5 months in the chemo-only group.

But the study began in 2005, before the advent of drugs like Avastin or Erbitux, meaning that investigators do not yet know if GOLFIG would outperform regimens that include those medications. This needs to be looked at, said Correale.

On the other hand, many patients do not see a benefit from biological agents such as Erbitux or Avastin because they have the wrong genetic profile, noted one outside expert.

"Essentially, we have a very problematic subset of patients with metastatic colorectal cancer which are limited to two lines of chemotherapy and [perhaps] one biological agent," said Dr. Igor Astsaturov, assistant professor of medical oncology at the Fox Chase Cancer Center in Philadelphia.

"For those patients, which are about one-third of the overall patient population, this [new finding] will be particularly welcome news," Astsaturov said, while adding the caution that the results are still preliminary.

However, clinical use of the protocol may be delayed further by the fact that "there is no direct commercial interest of pharmaceutical companies," noted Correale, who is nevertheless planning larger trials.

The costs associated with GOLFIG, he added, are "four-to-five times lower than that produced by the current use of Avastin or Erbitux with apparently similar therapeutic results."

Because this study was presented at a medical meeting, the findings should be viewed as preliminary until they are published in a peer-reviewed journal.

More information

There's more on colorectal cancer at the U.S. National Cancer Institute.

SOURCES: Pierpaolo Correale, M.D., Ph.D., oncologist, Siena University School of Medicine, Siena, Italy; Igor Astsaturov, M.D., Ph.D., assistant professor, medical oncology, Fox Chase Cancer Center, Philadelphia; presentation, Apr. 6, 2011, annual meeting, American Association for Cancer Research, Orlando


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Diabetes treatment may also provide protection against endometrial cancer
2. Treatment of Barretts esophagus may lower risk of esophageal cancer
3. Digoxin may be a possible treatment for prostate cancer
4. UCSF team discovers new way to predict breast cancer survival and enhance effectiveness of treatment
5. Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment
6. Assessing the value of treatments to increase height
7. New Drug May Boost Hepatitis C Treatment
8. UCSF researchers identify promising new treatment for childhood leukemia
9. Bariatric surgery highly cost-effective treatment for type 2 diabetes in the obese
10. Nerve Block Treatment May Ease Stubborn High Blood Pressure
11. Conflicts of Interest Cloud Heart Treatment Guidelines: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Immune-Boost Treatment Might Help Some With Advanced Colon Cancer
(Date:9/26/2017)... ... ... Founded as an independent institute in 1968, The Glenholme School devoted ... 2018, Glenholme will celebrate its first 50 years and set a course for the ... ponies, was generously donated by Jean White Van Sinderen to Devereux in 1968. The ...
(Date:9/26/2017)... ... September 26, 2017 , ... The Organizing ... and tactical plans for Pittcon 2018. As of July 1, Adrian C. Michael, ... his named vice president, Charles Gardner, (ChemImage Corporation) and selected chairs. ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Childhood Memories of a ... draw readers back, and help them relive their own youth. “Childhood Memories of a ... operator in the US Navy for nine years. He received his BS from ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... Time out ... and a little boy's newfound understanding that even grownups make mistakes. “Time Out for ... Southwestern United States for her entire life and whose passion for children inspired her ...
(Date:9/25/2017)... ... September 25, 2017 , ... The Renal Support Network (RSN) is ... improved functionality and enhanced rich content focused on RSN’s mission to empower people who ... hopeful about their future. , Our unique website is loaded with hundreds of ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
(Date:9/7/2017)... 2017  Eli Lilly and Company (NYSE: ... operations to more efficiently focus resources on developing ... Global workforce reductions, including those from a U.S. ... approximately 3,500 positions. With the ... of approximately $500 million that will begin to ...
Breaking Medicine Technology: